Lindegaard Jacob Christian, Petric Primoz, Schmid Maximilian Paul, Nesvacil Nicole, Haie-Meder Christine, Fokdal Lars Ulrik, Sturdza Alina Emiliana, Hoskin Peter, Mahantshetty Umesh, Segedin Barbara, Bruheim Kjersti, Huang Fleur, Rai Bhavana, Cooper Rachel, van der Steen-Banasik Elzbieta, Van Limbergen Erik, Pieters Bradley Rumwell, Tan Li-Tee, Nout Remi A, De Leeuw Astrid Agatha Catharina, Kirchheiner Kathrin, Spampinato Sofia, Jürgenliemk-Schulz Ina, Tanderup Kari, Kirisits Christian, Pötter Richard
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Department of Radiation Oncology, University Hospital Zürich, Switzerland.
Int J Radiat Oncol Biol Phys. 2022 Jun 1;113(2):379-389. doi: 10.1016/j.ijrobp.2022.02.005. Epub 2022 Feb 12.
A simple scoring system (T-score, TS) for integrating findings from clinical examination and magnetic resonance imaging (MRI) of the primary tumor at diagnosis has shown strong prognostic capability for predicting local control and survival in locally advanced cervical cancer treated with chemoradiation and MRI-guided brachytherapy (BT). The aim was to validate the performance of TS using the multicenter EMBRACE I study and to evaluate the prognostic implications of TS regression obtained during initial chemoradiation.
EMBRACE I recruited 1416 patients, of whom 1318 were available for TS. Patients were treated with chemoradiation followed by MRI-guided BT. A ranked ordinal scale of 0 to 3 points was used to assess 8 anatomic locations typical for local invasion of cervical cancer. TS was calculated separately at diagnosis (TS) and at BT (TS) by the sum of points obtained from the 8 locations at the 2 occasions.
Median TS and TS was 5 and 4, respectively. TS regression was observed in 71% and was an explanatory variable for BT technique (intracavitary vs intracavitary/interstitial) and major dose-volume histogram parameters for BT, such as high-risk clinical target (CTV), CTV D90 (minimal dose to 90% of the target volume), D2cm bladder (minimal dose to the most exposed 2 cm of the bladder), and D2cm rectum. TS regression (TS≤5) was associated with improved local control and survival and with less morbidity compared with patients with TS remaining high (>5) despite initial chemoradiation. TS regression was significant in multivariate analysis for both local control and survival when analyzed in consort with already established prognostic parameters related to the patient, disease, and treatment.
TS was validated in a multicenter setting and proven to be a strong multidisciplinary platform for integration of clinical findings and imaging with the ability to quantitate local tumor regression and its prognostic implications regarding BT technique, dose-volume histogram parameters, local control, survival, and morbidity.
一种用于整合诊断时原发性肿瘤临床检查和磁共振成像(MRI)结果的简单评分系统(T 评分,TS),已显示出在预测接受放化疗和 MRI 引导近距离放疗(BT)的局部晚期宫颈癌的局部控制和生存方面具有强大的预后能力。本研究旨在使用多中心 EMBRACE I 研究验证 TS 的性能,并评估初始放化疗期间获得的 TS 消退的预后意义。
EMBRACE I 研究招募了 1416 名患者,其中 1318 名可用于 TS 评估。患者接受放化疗,随后进行 MRI 引导的 BT。采用 0 至 3 分的排序量表评估宫颈癌局部侵犯典型的 8 个解剖部位。TS 在诊断时(TS₀)和 BT 时(TS₁)分别通过两次从 8 个部位获得的分数总和计算得出。
TS₀ 和 TS₁ 的中位数分别为 5 和 4。71%的患者观察到 TS 消退,TS 消退是 BT 技术(腔内 vs 腔内/间质)以及 BT 的主要剂量体积直方图参数的解释变量,如高危临床靶区(CTV)、CTV D90(靶体积 90%的最小剂量)、膀胱 D2cm(膀胱最暴露 2cm 的最小剂量)和直肠 D2cm。与初始放化疗后 TS 仍高(>5)的患者相比,TS 消退(TS₁≤5)与局部控制改善、生存改善以及更低的发病率相关。在与已确立的与患者、疾病和治疗相关的预后参数联合分析时,TS 消退在局部控制和生存的多因素分析中均具有显著性。
TS 在多中心环境中得到验证,被证明是一个强大的多学科平台,可整合临床发现和影像学,能够定量局部肿瘤消退及其对 BT 技术、剂量体积直方图参数、局部控制、生存和发病率的预后意义。